FDA Advisory Panel Recommends Novavax Covid-19 Vaccine In US


The advisory of the Food and Drug Administration (FDA) of the United States have voted to recommend the corona virus vaccine developed by Novavax for use in the adult people in the United States, which the company is hoping can possibly become the vaccine shot of choice among some of the vaccine sceptics of the United States.

The advisory panel has voted 21-0 with one abstention in the favour of the Novavax covid-19 vaccine for the adult people of the United States. If the US FDA follows the recommendation and if it authorizes the vaccine shot, then it is going to be the fourth corona virus vaccine that will be available for use in the adult people of the United States.

The corona virus vaccine shot of Novavax is now hoping to gain a foothold within around 27 million adults of the United States, who are yet to be vaccinated and specifically, the people who do not want to receive a vaccine such as the shots developed by Moderna or Pfizer/BioNTech that are based on the messenger RNA (mRNA) technology.

READ  US CDC Published New Monkeypox Vaccine Guidelines

The officials of the US FDA has also agreed that, having a vaccine shot based on protein such as the vaccine developed by Novavax might be helpful in driving more covid-19 vaccine acceptance among the hesitant people. Peter Marks, official of US FDA said, they do have an issue with the uptake of the corona virus vaccine that has been very serious in the United States.